Advertisement
LRMR vs MLTX
Which Stock Would AI Choose? Larimar Therapeutics (LRMR) vs. MoonLake Immunotherapeutics (MLTX) Stock Comparison
Key Takeaways
- Both companies are clinical-stage biotechnology developers advancing a single lead drug candidate toward regulatory decisions, making this a comparison of binary catalysts rather than established revenue streams.
- LRMR is advancing nomlabofusp for Friedreich's ataxia (FA, a rare inherited neurological disorder) under an FDA Breakthrough Therapy Designation with a rolling BLA (Biologics License Application, a request for marketing approval) already underway.
- MLTX is pursuing sonelokimab for hidradenitis suppurativa (HS, a chronic inflammatory skin condition) and has submitted its BLA to the FDA after earlier mixed Phase 3 results triggered sharp volatility.
- Tickeron AI Verdict: Based on trend consistency, regulatory momentum, and relative stability, the AI currently favors LRMR over MLTX in this head-to-head comparison.
- For more detail on each company's latest developments and intraday moves, explore the LRMR Major News and LRMR Today's Price Move pages, as well as MLTX Major News and MLTX Today's Price Move.
- To see how automated strategies are positioned across this pair and the broader market, explore Trending AI Robots.
Introduction
This stock comparison examines two clinical-stage biotechnology companies that, despite operating in different disease areas, share a strikingly similar investment profile: each depends on a single lead drug candidate approaching a critical FDA (Food and Drug Administration) decision. LRMR (Larimar Therapeutics) and MLTX (MoonLake Immunotherapeutics) both carry high analyst price targets and substantial downside risk, making relative performance and market positioning especially relevant. This comparison is most useful for growth-oriented and event-driven investors who follow biotech catalysts, as well as traders seeking to understand how regulatory milestones reshape sentiment in pre-revenue companies.
LRMR Overview and Recent Performance
Larimar Therapeutics is a clinical-stage biotech focused on rare diseases, with its lead candidate nomlabofusp designed to treat Friedreich's ataxia, a progressive and often fatal inherited condition caused by frataxin deficiency. In recent weeks, the company has strengthened its regulatory positioning: the FDA granted nomlabofusp Breakthrough Therapy Designation, and Larimar has begun a rolling BLA submission seeking accelerated approval, with completion expected in the second half of 2026.
Recent market activity has reflected this regulatory progress, with shares trading in the low single digits while carrying a consensus "Strong Buy" rating and a substantially higher average price target. The company recently appointed a new President and COO, and completed an upsized public offering that extended its projected cash runway into 2027, reducing near-term financing overhang. Sentiment has been shaped by positive open-label study data and alignment with the FDA on a surrogate endpoint, though execution risk around the BLA and confirmatory Phase 3 trial remains.
MLTX Overview and Recent Performance
MoonLake Immunotherapeutics is a clinical-stage biotech developing sonelokimab, a Nanobody-based therapy for inflammatory diseases, primarily moderate-to-severe hidradenitis suppurativa. The stock has experienced extreme volatility over the past year: shares fell sharply in late 2025 after Phase 3 results narrowly missed a key composite analysis, then recovered after a January 2026 Type B meeting with the FDA cleared a path to BLA submission without additional trials.
In recent weeks, MoonLake submitted its BLA for sonelokimab and reported third-quarter results alongside positive Week 16 data. The shares trade near $11 to $12, well below a consensus "Strong Buy" rating with an average target near $40, reflecting both the opportunity and the lingering uncertainty from the earlier data miss. Insider selling and a mixed analyst landscape, including some Sell ratings, have tempered enthusiasm even as the regulatory timeline has advanced.
Trending AI Robots
Tickeron operates a large library of AI trading bots that collectively scan thousands of tickers, each running distinct strategies, timeframes, and risk parameters. Only a small, curated subset earns placement in the Trending AI Robots section, which highlights the bots best suited to current market conditions. These bots vary widely in trading style, holding period, historical performance, and the specific tickers they follow, allowing traders to evaluate automation options that match their own approach. For readers tracking the LRMR versus MLTX comparison, reviewing the Trending AI Robots page can offer additional perspective on how automated systems are reading momentum and positioning in real time.
Head-to-Head Comparison
While both are pre-revenue biotechs with single-asset risk, the two differ meaningfully in market positioning. LRMR benefits from a clearly defined accelerated-approval path, Breakthrough Therapy Designation, and a cash runway extending into 2027, which has supported relatively steadier price behavior in recent weeks. Its risk centers on a rare-disease market and the execution of a confirmatory trial.
MLTX targets a larger dermatology market with an established competitor landscape, but its path has been more volatile, including a near-90% single-event drawdown and ongoing litigation tied to the earlier data miss. Its growth drivers depend heavily on FDA acceptance and commercial execution, while its risk factors include insider selling and a more divided analyst base. On stability and trend consistency, LRMR currently presents the smoother profile; on total addressable market and potential upside, MLTX offers a larger, albeit less certain, opportunity.
Tickeron AI Verdict
Based on observable factors—trend consistency, regulatory momentum, balance-sheet runway, and relative price stability—Tickeron's AI would currently lean toward LRMR in this comparison. The company's Breakthrough Therapy Designation, an already-initiated rolling BLA, and extended cash runway suggest a more orderly catalyst sequence with lower near-term volatility than MLTX, whose recent history includes a sharper drawdown and greater dispersion in analyst sentiment. This assessment is probabilistic rather than definitive: both names carry material binary risk, and either could re-rate substantially on future regulatory news.
Disclaimer
The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.
To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is LRMR is a Hold and MLTX is a StrongBuy.
LRMR's RSI Indicator climbs out of oversold territory
The RSI Indicator for LRMR moved out of oversold territory on October 20, 2026. This could be a sign that the stock is shifting from a downward trend to an upward trend. Traders may want to buy the stock or call options. The A.I.dvisor looked at 34 similar instances when the indicator left oversold territory. In 30 of the 34 cases the stock moved higher. This puts the odds of a move higher at 88%.
Technical Analysis (Indicators)
Bullish Trend Analysis
The Momentum Indicator moved above the 0 level on October 27, 2026. You may want to consider a long position or call options on LRMR as a result. In 76 of 94 past instances where the momentum indicator moved above 0, the stock continued to climb. The odds of a continued upward trend are 81%.
The Moving Average Convergence Divergence (MACD) for LRMR just turned positive on October 21, 2026. Looking at past instances where LRMR's MACD turned positive, the stock continued to rise in 45 of 51 cases over the following month. The odds of a continued upward trend are 88%.
Following a +12.55% 3-day Advance, the price is estimated to grow further. Considering data from situations where LRMR advanced for three days, in 214 of 255 cases, the price rose further within the following month. The odds of a continued upward trend are 84%.
LRMR may jump back above the lower band and head toward the middle band. Traders may consider buying the stock or exploring call options.
Bearish Trend Analysis
The Stochastic Oscillator may be shifting from an upward trend to a downward trend. In 49 of 56 cases where LRMR's Stochastic Oscillator exited the overbought zone, the price fell further within the following month. The odds of a continued downward trend are 88%.
Following a 3-day decline, the stock is projected to fall further. Considering past instances where LRMR declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 89%.
The Aroon Indicator for LRMR entered a downward trend on October 27, 2026. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options.
Fundamental Analysis (Ratings)
The Tickeron PE Growth Rating for this company is 13 (best 1 - 100 worst), pointing to outstanding earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron Seasonality Score of 38 (best 1 - 100 worst) indicates that the company is fair valued in the industry. The Tickeron Seasonality score describes the variance of predictable price changes around the same period every calendar year. These changes can be tied to a specific month, quarter, holiday or vacation period, as well as a meteorological or growing season.
The Tickeron Valuation Rating of 58 (best 1 - 100 worst) indicates that the company is fair valued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (1.949) is normal, around the industry mean (3.498). P/E Ratio (-1.189) is within average values for comparable stocks, (-1.193). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (9.059). Dividend Yield (0.000) settles around the average of (130.981) among similar stocks. P/S Ratio (0.000) is also within normal values, averaging (440.869).
The Tickeron Price Growth Rating for this company is 78 (best 1 - 100 worst), indicating slightly worse than average price growth. LRMR’s price grows at a lower rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron SMR rating for this company is 100 (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron Profit vs. Risk Rating rating for this company is 100 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. LRMR’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 93, placing this stock worse than average.
MLTX in upward trend: price rose above 50-day moving average on November 09, 2026
MLTX moved above its 50-day moving average on November 09, 2026 date and that indicates a change from a downward trend to an upward trend. In 40 of 45 similar past instances, the stock price increased further within the following month. The odds of a continued upward trend are 89%.
Technical Analysis (Indicators)
Bullish Trend Analysis
The RSI Oscillator points to a transition from a downward trend to an upward trend -- in cases where MLTX's RSI Indicator exited the oversold zone, 11 of 16 resulted in an increase in price. Tickeron's analysis proposes that the odds of a continued upward trend are 69%.
The Stochastic Oscillator suggests the stock price trend may be in a reversal from a downward trend to an upward trend. 55 of 69 cases where MLTX's Stochastic Oscillator exited the oversold zone resulted in an increase in price. Tickeron's analysis proposes that the odds of a continued upward trend are 80%.
The Momentum Indicator moved above the 0 level on November 09, 2026. You may want to consider a long position or call options on MLTX as a result. In 85 of 107 past instances where the momentum indicator moved above 0, the stock continued to climb. The odds of a continued upward trend are 79%.
The Moving Average Convergence Divergence (MACD) for MLTX just turned positive on October 20, 2026. Looking at past instances where MLTX's MACD turned positive, the stock continued to rise in 45 of 53 cases over the following month. The odds of a continued upward trend are 85%.
Following a +16.85% 3-day Advance, the price is estimated to grow further. Considering data from situations where MLTX advanced for three days, in 257 of 306 cases, the price rose further within the following month. The odds of a continued upward trend are 84%.
Bearish Trend Analysis
Following a 3-day decline, the stock is projected to fall further. Considering past instances where MLTX declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 80%.
MLTX broke above its upper Bollinger Band on October 22, 2026. This could be a sign that the stock is set to drop as the stock moves back below the upper band and toward the middle band. You may want to consider selling the stock or exploring put options.
The Aroon Indicator for MLTX entered a downward trend on October 27, 2026. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options.
Fundamental Analysis (Ratings)
The Tickeron PE Growth Rating for this company is 12 (best 1 - 100 worst), pointing to outstanding earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron Valuation Rating of 38 (best 1 - 100 worst) indicates that the company is fair valued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (2.292) is normal, around the industry mean (3.498). P/E Ratio (-3.003) is within average values for comparable stocks, (-1.193). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (9.059). Dividend Yield (0.000) settles around the average of (130.981) among similar stocks. P/S Ratio (0.000) is also within normal values, averaging (440.869).
The Tickeron Price Growth Rating for this company is 57 (best 1 - 100 worst), indicating steady price growth. MLTX’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron Seasonality Score of 75 (best 1 - 100 worst) indicates that the company is slightly overvalued in the industry. The Tickeron Seasonality score describes the variance of predictable price changes around the same period every calendar year. These changes can be tied to a specific month, quarter, holiday or vacation period, as well as a meteorological or growing season.
The Tickeron Profit vs. Risk Rating rating for this company is 96 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. MLTX’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 93, placing this stock worse than average.
The Tickeron SMR rating for this company is 98 (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
LRMR | MLTX | ||
|---|---|---|---|
OUTLOOK RATING 1..100 | 12 | 32 | |
VALUATION overvalued / fair valued / undervalued 1..100 | 58 Fair valued | 38 Fair valued | |
PROFIT vs RISK RATING 1..100 | 100 | 96 | |
SMR RATING 1..100 | 100 | 98 | |
PRICE GROWTH RATING 1..100 | 78 | 57 | |
P/E GROWTH RATING 1..100 | 13 | 12 | |
SEASONALITY SCORE 1..100 | 38 | 75 |
Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.
MLTX's Valuation (38) in the null industry is in the same range as LRMR (58). This means that MLTX’s stock grew similarly to LRMR’s over the last 12 months.
MLTX's Profit vs Risk Rating (96) in the null industry is in the same range as LRMR (100). This means that MLTX’s stock grew similarly to LRMR’s over the last 12 months.
MLTX's SMR Rating (98) in the null industry is in the same range as LRMR (100). This means that MLTX’s stock grew similarly to LRMR’s over the last 12 months.
MLTX's Price Growth Rating (57) in the null industry is in the same range as LRMR (78). This means that MLTX’s stock grew similarly to LRMR’s over the last 12 months.
MLTX's P/E Growth Rating (12) in the null industry is in the same range as LRMR (13). This means that MLTX’s stock grew similarly to LRMR’s over the last 12 months.
| LRMR | MLTX | |
|---|---|---|
| RSI ODDS (%) | 2 days ago 88% | 2 days ago 69% |
| Stochastic ODDS (%) | 2 days ago 88% | 2 days ago 80% |
| Momentum ODDS (%) | 2 days ago 81% | 2 days ago 79% |
| MACD ODDS (%) | 2 days ago 88% | 2 days ago 85% |
| TrendWeek ODDS (%) | 2 days ago 82% | 2 days ago 83% |
| TrendMonth ODDS (%) | 2 days ago 81% | 2 days ago 87% |
| Advances ODDS (%) | 2 days ago 84% | 3 days ago 84% |
| Declines ODDS (%) | 10 days ago 89% | 7 days ago 80% |
| BollingerBands ODDS (%) | 2 days ago 71% | 2 days ago 79% |
| Aroon ODDS (%) | 2 days ago 89% | 2 days ago 86% |
Long-Term Analysis
It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is overvalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).
LRMR’s FA Score shows that 1 FA rating(s) are green while MLTX’s FA Score has 1 green FA rating(s).
- LRMR’s FA Score: 1 green, 4 red.
- MLTX’s FA Score: 1 green, 4 red.
Short-Term Analysis
It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.
If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.
LRMR’s TA Score shows that 5 TA indicator(s) are bullish while MLTX’s TA Score has 6 bullish TA indicator(s).
- LRMR’s TA Score: 5 bullish, 3 bearish.
- MLTX’s TA Score: 6 bullish, 3 bearish.
Price Growth
LRMR (@Biotechnology) experienced а +5.91% price change this week, while MLTX (@Biotechnology) price change was +7.35% for the same time period.
The average weekly price growth across all stocks in the @Biotechnology industry was +4.76%. For the same industry, the average monthly price growth was -2.90%, and the average quarterly price growth was -13.48%.
Reported Earning Dates
LRMR is expected to report earnings on Nov 11, 2026.
MLTX is expected to report earnings on Mar 04, 2027.
Industries' Descriptions
@Biotechnology (+4.76% weekly)Biotechnology involves genetic or protein engineering to produce medicines/therapies for treating and preventing ailments. The industry also provides crucial ingredients for diagnostics. This multi-billion-dollar industry is heavily focused on research and development, as companies attempt to continually come up with cutting-edge solutions for health. New discoveries for the treatment of diseases provide opportunities for growth for a company in this industry. Discoveries, however, must pass the regulatory approval from the U.S. Food and Drug Administration (FDA) before they can make it to markets. Amgen Inc., Gilead Sciences, Inc. and Celgene Corporation are examples of companies in this industry.
Advertisement
LRMR and
Correlation & Price change
A.I.dvisor indicates that over the last year, LRMR has been loosely correlated with AMLX. These tickers have moved in lockstep 45% of the time. This A.I.-generated data suggests there is some statistical probability that if LRMR jumps, then AMLX could also see price increases.
| Ticker / NAME | Correlation To LRMR | 1D Price Change % | ||
|---|---|---|---|---|
| LRMR | 100% | +6.32% | ||
| AMLX - LRMR | 45% Loosely correlated | +2.32% | ||
| CLDX - LRMR | 44% Loosely correlated | -1.89% | ||
| VIR - LRMR | 44% Loosely correlated | -3.63% | ||
| MLTX - LRMR | 42% Loosely correlated | -0.48% | ||
| SLDB - LRMR | 41% Loosely correlated | +2.14% | ||
More | ||||
| 1 Day | |||
|---|---|---|---|
| ETFs / NAME | Price $ | Chg $ | Chg % |
| BRLN | 50.72 | 0.30 | +0.59% |
| iShares Floating Rate Loan Active ETF (BRLN) | |||
| MBCE | 35.30 | 0.09 | +0.26% |
| Monarch Blue Chips Elite Index ETF (MBCE) | |||
| JMST | 50.93 | 0.01 | +0.02% |
| JPMorgan Ultra-Short Municipal Income ETF (JMST) | |||
| MLPR | 62.78 | N/A | N/A |
| ETRACS Quarterly Pay 1.5X Leveraged Alerian MLP Index ETN (MLPR) | |||
| CPER | 37.74 | -0.69 | -1.80% |
| United States Copper Index Fund (CPER) | |||